| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 17th September 2020 | Mark Anthony Mc Camish | 52,398 | Open or private purchase | $5.83 | $305,249.79 |
| 16th September 2020 | Mark Anthony Mc Camish | 118,602 | Open or private purchase | $5.73 | $679,968.99 |
| 2nd July 2020 | Jeffrey W Bird | 458,569 | Sale back to the issuer | $18.00 | $8,254,242.00 |
| 2nd July 2020 | Jeffrey W Bird | 20,475 | Sale back to the issuer | $18.00 | $368,550.00 |
| 2nd July 2020 | Jeffrey W Bird | 10,007 | Sale back to the issuer | $18.00 | $180,126.00 |
| 2nd July 2020 | Jeffrey W Bird | 45,402 | Sale back to the issuer | $18.00 | $817,236.00 |
| 23rd June 2020 | Ann D Rhoads | 4,000 | Open or private purchase | $20.00 | $80,000.00 |
| 12th June 2020 | Jeffrey W Bird | 7,281 | Grant/award etc. | $0.00 | |
| 7th April 2020 | Ann D Rhoads | 37,414 | Sale back to the issuer | $0.00 | |
| 7th April 2020 | Jeffrey W Bird | 215,375 | Sale back to the issuer | $0.00 |
Forty Seven
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014.
Ticker: FTSV
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1667633
Employees: 57
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
